Evelyn Hsieh1, Liana Fraenkel, Yang Han, Weibo Xia, Karl L Insogna, Michael T Yin, Ting Zhu, Xinqi Cheng, Taisheng Li. 1. aDepartment of Infectious Diseases, Peking Union Medical College Hospital, Beijing, China bSection of Rheumatology, Yale School of Medicine, New Haven, Connecticut, USA cDepartment of Endocrinology, Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Beijing, China dSection of Endocrinology, Yale School of Medicine, New Haven, Connecticut eDivision of Infectious Diseases, Columbia University Medical Center, New York, USA fClinical Laboratory, Peking Union Medical College Hospital, Beijing, China.
Abstract
OBJECTIVE: To examine longitudinal change in vitamin D binding protein (DBP) levels during the first year after initiation of tenofovir disoproxil fumarate (TDF)/lamivudine/efavirenz and compare these findings with concurrent changes in markers of skeletal metabolism. DESIGN: Secondary analysis of plasma samples collected from an ongoing multicenter clinical trial. METHODS: Plasma samples collected at 0, 24, and 48 weeks after initiation of TDF + lamivudine + efavirenz from 134 adult participants enrolled in a multicenter randomized trial were analyzed. Data regarding sociodemographic and clinical characteristics were obtained as part of the parent study. Laboratory analyses included plasma DBP, intact parathyroid hormone, total 25-hydroxy vitamin D, phosphorus, the bone resorption marker collagen type 1 cross-linked C-telopeptide, and the bone formation marker total procollagen type 1 N-terminal propeptide. Repeated measures analysis of variance was used to measure changes in biomarkers over time. RESULTS: Our sample included 108 men and 26 women (mean age 33.6 ± 9.6 years). Median levels of DBP increased significantly from baseline to 48 weeks [154 (91.8-257.4) versus 198.3 (119.6-351.9) μg/ml, P < 0.001]. A concurrent rise in intact parathyroid hormone levels was observed over the same period [32.3 (24.4-40.9) versus 45.2 (35.1-60.4) pg/ml, P < 0.001]; however, 25-hydroxy vitamin D and phosphorus levels remained stable. Bone resorption and formation markers rapidly increased from 0 to 24 weeks, followed by a slight decline or plateau, but remained significantly elevated at 48 weeks (P < 0.001). CONCLUSION: Our study provides longitudinal data supporting a potential role for DBP in bone loss associated with TDF-based therapy. Further research to elucidate the mechanistic pathways and clinical impact of these findings is warranted.
RCT Entities:
OBJECTIVE: To examine longitudinal change in vitamin D binding protein (DBP) levels during the first year after initiation of tenofovir disoproxil fumarate (TDF)/lamivudine/efavirenz and compare these findings with concurrent changes in markers of skeletal metabolism. DESIGN: Secondary analysis of plasma samples collected from an ongoing multicenter clinical trial. METHODS: Plasma samples collected at 0, 24, and 48 weeks after initiation of TDF + lamivudine + efavirenz from 134 adult participants enrolled in a multicenter randomized trial were analyzed. Data regarding sociodemographic and clinical characteristics were obtained as part of the parent study. Laboratory analyses included plasma DBP, intact parathyroid hormone, total 25-hydroxy vitamin D, phosphorus, the bone resorption marker collagen type 1 cross-linked C-telopeptide, and the bone formation marker total procollagen type 1 N-terminal propeptide. Repeated measures analysis of variance was used to measure changes in biomarkers over time. RESULTS: Our sample included 108 men and 26 women (mean age 33.6 ± 9.6 years). Median levels of DBP increased significantly from baseline to 48 weeks [154 (91.8-257.4) versus 198.3 (119.6-351.9) μg/ml, P < 0.001]. A concurrent rise in intact parathyroid hormone levels was observed over the same period [32.3 (24.4-40.9) versus 45.2 (35.1-60.4) pg/ml, P < 0.001]; however, 25-hydroxy vitamin D and phosphorus levels remained stable. Bone resorption and formation markers rapidly increased from 0 to 24 weeks, followed by a slight decline or plateau, but remained significantly elevated at 48 weeks (P < 0.001). CONCLUSION: Our study provides longitudinal data supporting a potential role for DBP in bone loss associated with TDF-based therapy. Further research to elucidate the mechanistic pathways and clinical impact of these findings is warranted.
Authors: Mar Masiá; Sergio Padilla; Catalina Robledano; Natividad López; José Manuel Ramos; Felix Gutiérrez Journal: AIDS Res Hum Retroviruses Date: 2011-07-19 Impact factor: 2.205
Authors: Jean C Yombi; Anton Pozniak; Marta Boffito; Rachael Jones; Saye Khoo; Jeremy Levy; Frank A Post Journal: AIDS Date: 2014-03-13 Impact factor: 4.177
Authors: Michelle R Denburg; Heidi J Kalkwarf; Ian H de Boer; Martin Hewison; Justine Shults; Babette S Zemel; David Stokes; Debbie Foerster; Benjamin Laskin; Anthony Ramirez; Mary B Leonard Journal: Pediatr Nephrol Date: 2013-06-02 Impact factor: 3.714
Authors: E Hsieh; L Fraenkel; W Xia; Y Y Hu; Y Han; K Insogna; M T Yin; J Xie; T Zhu; T Li Journal: Osteoporos Int Date: 2014-09-16 Impact factor: 4.507
Authors: Mark R Nelson; Christine Katlama; Julio S Montaner; David A Cooper; Brian Gazzard; Bonaventura Clotet; Adriano Lazzarin; Knud Schewe; Joep Lange; Christina Wyatt; Sue Curtis; Shan-Shan Chen; Stephen Smith; Norbert Bischofberger; James F Rooney Journal: AIDS Date: 2007-06-19 Impact factor: 4.177
Authors: Camille E Powe; Catherine Ricciardi; Anders H Berg; Delger Erdenesanaa; Gina Collerone; Elizabeth Ankers; Julia Wenger; S Ananth Karumanchi; Ravi Thadhani; Ishir Bhan Journal: J Bone Miner Res Date: 2011-07 Impact factor: 6.741
Authors: Karen Klassen; Adrian R Martineau; Robert J Wilkinson; Graham Cooke; Alan P Courtney; Mary Hickson Journal: PLoS One Date: 2012-09-12 Impact factor: 3.240
Authors: Julie J Kim-Chang; Lorena Wilson; Cliburn Chan; Bernard Fischer; Guglielmo Venturi; Maureen M Goodenow; Grace Aldrovandi; Thomas J Weber; John W Sleasman Journal: AIDS Res Hum Retroviruses Date: 2019-06-27 Impact factor: 2.205
Authors: Michael T Yin; Ellen S Chan; Todd T Brown; Pablo Tebas; Grace A McComsey; Kathleen M Melbourne; Andrew Napoli; William R Hardin; Heather J Ribaudo; Edgar T Overton Journal: AIDS Date: 2017-11-13 Impact factor: 4.177
Authors: Peter L Havens; Charles B Stephensen; Marta D Van Loan; Gertrud U Schuster; Leslie R Woodhouse; Patricia M Flynn; Catherine M Gordon; Cynthia G Pan; Brandy Rutledge; D Robert Harris; Georgine Price; Alyne Baker; William A Meyer; Craig M Wilson; Rohan Hazra; Bill G Kapogiannis; Kathleen Mulligan Journal: Clin Infect Dis Date: 2018-01-06 Impact factor: 9.079
Authors: Janaina Ramalho; Carolina Steller Wagner Martins; Juliana Galvão; Luzia N Furukawa; Wagner V Domingues; Ivone B Oliveira; Luciene M Dos Reis; Rosa Mr Pereira; Thomas L Nickolas; Michael T Yin; Margareth Eira; Vanda Jorgetti; Rosa Ma Moyses Journal: J Bone Miner Res Date: 2019-07-03 Impact factor: 6.390